Drug intelligence / Profile preview

ZG016

Development stage: Preclinical
Lead developer: Suzhou Zelgen Biopharmaceuticals
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

ZG016 is a preclinical-stage drug candidate being developed by Suzhou Zelgen Biopharmaceuticals (Zelgen) for the treatment of various neoplasms (cancers). The compound is part of Zelgen's bispecific and multispecific antibody platform programs, which include the TriGen, CheckGen, and TGen platforms designed to develop novel antibody molecules targeting immune checkpoints and other cancer-related targets. While the specific molecular targets and exact mechanism of action for ZG016 have not been publicly disclosed, it is categorized as a multispecific antibody or T-cell engager within Zelgen's oncology pipeline.

Beyond the preview

Go deeper on ZG016.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ZG016.

Explore the full profile